Feature | June 07, 2013

Study Suggests New Role for ECMO in Patients With Cardiac Arrest, Profound Shock

Procedure traditionally used during heart surgery and in the ICU may show promise as a rescue strategy for select cardiac arrest patients

June 7, 2013 — Extracorporeal membrane oxygenation (ECMO), a procedure traditionally used during cardiac surgeries and in the intensive care unit (ICU) that functions as an artificial replacement for a patient's heart and lungs, has also been used to as a resuscitation device for cardiac arrest victims in Japan, Taiwan and South Korea. Now, a novel study of this technique in the United States has been completed by researchers at the Perelman School of Medicine at the University of Pennsylvania, indicating a potential role for this intervention to save patients who are unable to be resuscitated through conventional measures.

ECMO directly oxygenates and removes carbon dioxide from the blood, and is used for both respiratory and cardiac failure. The procedure requires 24/7 monitoring and care for the duration of the treatment, but it provides a critical backup for patients whose heart and lungs are so severely diseased or damaged that they can no longer function.

"Over the last decade, we have made great strides in the field of cardiac resuscitation science, including the development of novel methods of therapeutic hypothermia and the use of cardiac bypass following cardiac arrest," said lead study author David Gaieski, M.D., an associate professor of Emergency Medicine in the Perelman School of Medicine and clinical director of Penn's Center for Resuscitation Science. "Yet cardiac arrests still take the lives of more than 300,000 Americans each year, and we are continuing to explore how to use new and expanded strategies to help save these patients. Based on the work of our colleagues in Asia, we sought to report our own experience using ECMO for a select set of patients with refractory cardiac arrest and profound shock."

For the study, the research team used a collaborative approach between clinicians in the Department of Emergency Medicine and surgeons within the Division of Cardiovascular Surgery at Penn to assess the outcomes for select patients undergoing ECMO presenting in the emergency department (ED) and for in-hospital cardiac arrests at the Hospital of the University of Pennsylvania.

They studied the approach in patients who otherwise would have died — who were unable to be resuscitated through CPR and defibrillation and who would not have been eligible for other post-arrest therapies such as therapeutic hypothermia.

Inclusion criteria for ED patients included witnessed arrest, bystander CPR and an initial shockable rhythm. For in-patient arrests, inclusion criteria included presumed cardiac etiology of arrest or refractory shock unresponsive to conventional interventions. Main variables were whether a patient was in cardiac arrest or profound shock and location of patient at time of initiation of ECMO, with the primary outcome of survival to hospital discharge.

Thirty-three patients were included in the study. Of these patients, the mean age was 50 years and 70 percent were men. Three-quarters of the patients were treated for cardiac arrest, and the remainder were treated for refractory shock. Using the ECMO strategy, 21 percent of the patients survived to discharge and five were neurologically intact.

"This preliminary study shows that using ECMO in a collaborative model between emergency physicians and cardiothoracic surgeons can be a useful rescue tool in select cardiac arrest and shock patients. The results are promising given that among patients that regain a pulse after cardiac arrest, only one out of three survive to hospital discharge," said senior study author Michael Acker, M.D., chief, Division of Cardiovascular Surgery at Penn Medicine.

For more information: www.uphs.upenn.edu

Related Content

St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Heartware HVAD, ventricular assist device, artificial heart, Medtronic
News | October 05, 2016
October 5, 2016 — Medtronic said two previously communicated global voluntary recalls related to the HeartWare Intern
CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart| September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart| September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
Carew Medical Wear, Rod Carew, undergarments, LVAD, HeartMate II, American Heart Association
News | Ventricular Assist Devices (VAD)| August 11, 2016
August 11, 2016 — Carew Medical Wear Inc., a custom medical outfit company specializing in...
sudden cardiac arrest, out-of-hospital, comatose patients, University of Arizona study, wake up
News | Sudden Cardiac Arrest| July 13, 2016
Physicians may be drawing conclusions too soon about survival outcomes of patients who suffered a cardiac arrest...
Overlay Init